The effect of intravenous lidocaine on EC50 and EC95 of consciousness loss induced by propofol

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045063

Enrollment

Unknown

Registered

2021-04-04

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulterine diseases

Interventions

experimental group:lidocaine

control group:None

Eligibility

Sex/Gender

Female

Age

10 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Patients requiring general anesthesia for elective surgery; 2.ASA grade I-II; 3.Aged 18-60 years, BMI 18-24kg/m2.

Exclusion criteria

Exclusion criteria: 1.Patients with basic diseases of the central nervous system, cardiovascular and cerebrovascular diseases, abnormal liver and kidney function, abnormal lung function, arrhythmia; 2.Patients with chronic pain treated with opioids for a long time; 3.Patients with long-term use of drugs such as diazepam; 4.Patients with lidocaine allergy.

Design outcomes

Primary

Measure	Time frame
Half effective dose;	—

Countries

China

Contacts

Public ContactChen Xinzhong

Women's Hospital School of Medicine Zhejiang University

chenxinz@zju.edu.cn+86 13575738058

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026